Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats

Brain Research

Volumn 754, Issue 1-2, 1997, Pages 181-186

  Sethy, Vimala H ^a   Wu, Haiyan ^a   Oostveen, Jo A ^a   Hall, Edward D ^a  

^a PFIZER INC   (United States)

Author keywords

3 acetylpyridine; ATP; bromocriptine; cerebellum; cGMP; motor coordination; pramipexole

Indexed keywords

3 ACETYLPYRIDINE; ADENOSINE TRIPHOSPHATE; BROMOCRIPTINE; CYCLIC GMP; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CEREBELLUM; CONTROLLED STUDY; HISTOLOGY; MALE; MOTOR COORDINATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZOTHIAZOLES; BODY TEMPERATURE; BROMOCRIPTINE; CEREBELLUM; CYCLIC GMP; DOPAMINE AGONISTS; MALE; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OLIVARY NUCLEUS; PYRIDINES; RATS; RATS, WISTAR; THIAZOLES;

EID: 0030996245     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00075-9     Document Type: Article

References (23)

1. Balaban, C.D., Central neurotoxic effects of intraperitoneally administered harmaline and niacinamide in Sprague-Dawley and Long Evans rats: A critical review of central 3-acetylpyridine toxicity, Brain Res. Rev., 9 (1985) 21-42.
2. Biggio, G., Costa, E. and Guidotti, A., Pharmacologically induced changes in the 3′ ,5′ cyclic guanosine monophosphate content of rat cerebellum cortex: Difference between apomorphine, haloperidol and harmaline, J. Pharmacol. Exp. Ther., 200 (1977) 207-215.
3. Delbarre, B., Delbarre, G., Rochat, C. and Calinon, F., Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, aminoacids and free radicals in gerbil brain after cerebral ischemia, Mol. Chem. Neuropathol., 26 (1995) 43-52.
4. Desclin, J.C. and Escubi, J., Effect of 3-acetylpyridine on the central nervous system of the rat as demonstrated by silver methods, Brain Res., 11 (1974) 349-364.
5. Felton, D.L., Felton, S.Y., Fuller, R.W., Romano, T.D., Smalstig, E.B., Wong, D.T. and Clemess, J.A., Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats, Neurobiol. Aging, 13 (1992) 339-351.
6. 3 agonist pramipexole against post-ischemic or methamphetamine-induced degeneration of nigrostriatal neurons, Brain Res., (1996) in press.
7. Koe, K.B. and Lebel, L.A., Contrasting effects of ethyl-β-carboline-3-carboxylate (β-CCE) and diazepam on cerebellar cGMP content and antagonism of both effects by Ro 15-1788, a specific benzodiazepine receptor blocker, Eur. J. Pharmacol., 90 (1983) 97-102.
8. Kondo, T., Ito, T. and Sugita, Y., Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum, Ann. NY Acad. Sci., 738 (1994) 222-229.
9. Lust, W.D., Feussner, G.K., Barbehenn, E.K. and Passonneau, J.V., The enzymatic measurement of adenine nucleotide and P-creatine in picomole amounts, Anal. Biochem., 110 (1981) 258-266.
10. Mao, C.C., Guidotti, A. and Costa, E., Inhibition by diazepam of the tremor and increase of cerebellar cGMP content elicited by harmaline, Brain Res., 83 (1975a) 516-519.
11. Mao, C.C., Guidotti, A. and Costa, E., Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action of diazepam, Naunyn-Schmiedeberg's Arch. Pharmacol., 289 (1975b) 369-378.
12. 4 receptors, Eur. J. Pharmacol., 290 (1995) 29-36.
13. Oostveen, J.A., Timby, K. and Williams, L.R., Prediction of cerebral ischemia by ophthalmoscopy after carotid occlusion in gerbils, Stroke, 23 (1992) 1588-1594.
14. Sam, E.E. and Verbeke, N., Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism, J. Neural Transm., 10 (1995) 115-127.
15. 2 receptor agonists with high and low efficacies, Eur. J. Pharmacol., 211 (1992) 9-14.
16. Schulz, J.B., Henshaw, D.R., Siwek, D., Jenkins, E.G., Ferrante, R.J., Cipolloni, P.B., Kowall, N.W., Rosen, B.R. and Beal, M.F., Involvement of free radicals in excitotoxicity in vivo, J. Neurochem., 64 (1995) 2239-2247.
17. Schulz, J.B., Henshaw, D.R., Jenkins, E.G., Ferrante, R.J., Kowall, N.W., Rosen, B.R. and Beal, M.F., 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum, J. Cereb. Blood Flow Metab., 14 (1994) 1024-1029.
18. Sethy, V.H., Ellerbrock, B.R. and Wu, H., U-95666A: A potential antiparkinson drug, Neurosci. Abstr., 21 (1995) 1254.
19. Sethy, V.H., Ellerbrock, B.R. and Wu, H., U-95666E: A potential antiparkinsonian drug with anxiolytic activity, Neuropsychopharmacology, (1996) in press.
20. Sethy, V.H. and Oien, T.T., Role of cGMP in the mechanism of anxiolytic activity of U-78875, Pharmacol. Biochem. Behav., 39 (1991) 379-382.
21. Sethy, V.H., Wu, H., Oostveen, J.A. and Hall, E.D., Neuroprotective effects of the pyrrolopyrimidine U-104067F in 3-acetylpyridine treated rats, Exp. Neurol., 140 (1996) 79-83.
22. Tang, A.H., Franklin, S.R., Himes, C.S. and Ho, P.M., Behavioral effects of U-78875, a quanoxalinone anxiolytic with potent benzodiazepine antagonist activity, J. Pharmacol. Exp. Ther., 259 (1991) 248-254.
23. Yoshikawa, T., Minamiyama, Y., Naito, Y. and Kondo, M., Antioxidant properties of bromocriptine, a dopamine agonist, J. Neurochem., 62 (1994) 1034-1038.